Creatine is an endogenous guanidino compound synthesized from arginine, glycine, and methionine in the liver, kidney, and pancreas. In the brain, creatine and its phosphorylated form phosphocreatine (PCr) serve as the primary temporal and spatial energy buffer, maintaining ATP homeostasis during periods of high metabolic demand through the creatine kinase (CK) shuttle system[@wallimann2011][@wyss2000]. The brain, despite representing only 2% of body mass, consumes approximately 20% of total energy expenditure, making it exquisitely vulnerable to bioenergetic failure — a pathological hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS)[@beal2000]. Oral creatine supplementation increases brain creatine and PCr concentrations by 5–15% as measured by ³¹P-magnetic resonance spectroscopy (MRS), providing a rationale for neuroprotection through enhanced bioenergetic buffering[@dechent1999]. Despite promising preclinical results across multiple disease models, large clinical trials — notably NINDS NET-PD LS-1 in PD and CREST-E in HD — have yielded neutral primary outcomes, prompting reassessment of dosing strategies, patient selection, and combination approaches. This monograph synthesizes the molecular pharmacology, preclinical and clinical evidence, and practical considerations for creatine in neurodegeneration, with a dedicated section on progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
| Dimension |
Score (0–10) |
Rationale |
| Mechanistic Clarity |
8 |
CK shuttle, PCr/ATP buffering, mitochondrial permeability transition pore (mPTP) inhibition well characterized |
| Clinical Evidence |
3 |
NET-PD LS-1 and CREST-E neutral on primary endpoints; no PSP/CBS-specific trials |
| Preclinical Evidence |
7 |
Consistent neuroprotection in MPTP, 3-NP, SOD1(G93A), R6/2 models |
| Replication |
5 |
Preclinical findings replicated; clinical findings consistently neutral |
| Effect Size |
3 |
Preclinical: 15–25% neuronal survival improvement; clinical: no significant effect on primary outcomes |
| Safety/Tolerability |
9 |
Excellent safety at 5 g/day for years; mild GI and weight gain only |
| Biological Plausibility |
8 |
Energy failure is a convergent mechanism in all NDDs; creatine directly addresses this |
| Actionability |
7 |
Inexpensive, widely available, well-characterized dosing; limited by negative trial results |
| Total |
50/80 |
|
¶ Molecular Pharmacology and Mechanism of Action
The creatine kinase system functions as a spatial and temporal energy buffer in the brain[@wallimann2011][@wyss2000]:
- Mitochondrial CK (MtCK): Located in the mitochondrial intermembrane space, MtCK transfers a phosphoryl group from ATP generated by oxidative phosphorylation to creatine, producing PCr and ADP. The ADP is recycled back into the matrix for rephosphorylation.
- Cytosolic CK (BB-CK): Brain-type cytosolic CK regenerates ATP from PCr at sites of energy consumption (synaptic terminals, ion pumps, cytoskeletal dynamics), providing instantaneous ATP buffering without requiring proximity to mitochondria.
- Spatial buffering: PCr diffuses faster than ATP through the cytoplasm, effectively transporting high-energy phosphate bonds from mitochondria to distant consumption sites — critical in neurons with long axons.
This system is compromised in neurodegeneration. In AD, BB-CK is oxidatively modified and inactivated in hippocampal neurons, reducing PCr/ATP buffering capacity by up to 40%[@aksenov2000]. In PD, mitochondrial Complex I dysfunction impairs the MtCK substrate supply. In HD, mutant huntingtin directly interacts with MtCK, displacing it from the inner mitochondrial membrane[@kim2010].
1. Bioenergetic Buffering. By increasing intracellular PCr stores, creatine supplementation expands the temporal buffer against acute energy depletion. In brain slices, creatine pretreatment delays anoxic depolarization by 50–75%, providing neurons critical time to survive ischemic insults[@balestrino1999].
2. Mitochondrial Permeability Transition Pore (mPTP) Inhibition. MtCK bound to the inner mitochondrial membrane stabilizes mitochondrial contact sites and directly inhibits opening of the mPTP — a key trigger for apoptotic cell death. Creatine supplementation enhances MtCK binding to the inner membrane, reducing mPTP sensitivity to calcium and reactive oxygen species (ROS)[@ogorman1997][@dolder2003].
3. Anti-excitotoxic Effects. Creatine loading reduces glutamate-induced excitotoxicity by maintaining ATP supply for Na⁺/K⁺-ATPase function, preserving membrane potential and preventing pathological calcium influx through NMDA receptors[@brewer2000]. This mechanism is directly relevant to the excitotoxic component of motor neuron degeneration in ALS and cortical neurodegeneration in AD.
4. Antioxidant Activity. Creatine demonstrates direct free radical scavenging activity against superoxide, peroxynitrite, and ABTS radicals in vitro[@lawler2002]. In vivo, creatine supplementation reduces 8-hydroxy-2'-deoxyguanosine (8-OHdG, a marker of oxidative DNA damage) in the striatum of 3-nitropropionic acid (3-NP)-treated rats by 35%[@andreassen2001].
5. Anti-apoptotic Signaling. Creatine activates the Akt/PKB survival pathway, phosphorylating and inactivating the pro-apoptotic protein Bad and increasing Bcl-2 expression. Creatine also inhibits caspase-3 activation in neurons exposed to amyloid-β or 6-OHDA[@cunha2013].
6. Anti-inflammatory Effects. In microglial cell cultures, creatine reduces LPS-stimulated TNF-α, IL-1β, and IL-6 production by 30–50%, possibly through AMPK-mediated NF-κB suppression[@lenz2007].
graph TD
subgraph "Creatine Metabolism"
A["Oral Creatine Monohydrate (3-5 g/day)"] --> B["Intestinal Absorption (SLC6A8 Transporter)"]
B --> C["Blood → BBB Transport (SLC6A8)"]
C --> D["Neuronal Creatine Pool"]
end
subgraph "CK Energy Shuttle"
D --> E["Mitochondrial CK: ATP + Cr → PCr + ADP"]
E --> F["Cr Diffusion to Consumption Sites"]
F --> G["Cytosolic BB-CK: PCr + ADP → ATP + Cr"]
end
subgraph "Neuroprotective Outputs"
G --> H["↑ ATP at Synapses & Ion Pumps"]
E --> I["mPTP Stabilization → ↓ Apoptosis"]
H --> J["↓ Excitotoxicity (Na⁺/K⁺-ATPase)"]
D --> K["↓ ROS / ↓ Oxidative DNA Damage"]
D --> L["↑ Akt/PKB → ↓ Caspase-3"]
D --> M["↓ Microglial TNF-α/IL-1β"]
end
H --> N["Neuroprotection in PD/HD/ALS/PSP"]
I --> N
J --> N
K --> N
L --> N
M --> N
style A fill:#FFE0B2
style D fill:#C8E6C9
style E fill:#BBDEFB
style N fill:#E1BEE7
In the MPTP mouse model, creatine supplementation (2% diet × 2 weeks pretreatment) protected 68% of dopaminergic neurons in the substantia nigra compared to 38% survival in controls, with parallel preservation of striatal dopamine content and motor function[@matthews1999]. The protective effect was dose-dependent and associated with increased PCr/Cr ratio and reduced mitochondrial Complex I dysfunction. In the 6-OHDA rat model, creatine (300 mg/kg oral × 14 days) reduced amphetamine-induced rotational asymmetry by 45% and attenuated TH-positive neuron loss by 35%[@andres2005].
In the R6/2 transgenic HD mouse, creatine supplementation (2% diet from weaning) extended median survival by 17.4% (from 86.7 to 101.8 days), reduced brain atrophy by 25%, and delayed the onset of motor symptoms by 12 days[@andreassen2001]. The 3-NP rat model (which mimics HD-like mitochondrial Complex II inhibition) showed that creatine preloading protected 80% of striatal neurons against 3-NP-induced lesions versus 35% survival in controls[@matthews1998]. These results formed the rationale for the CREST-E clinical trial.
In the SOD1(G93A) transgenic ALS mouse, creatine supplementation (2% diet) extended survival by 12 days (p < 0.01), delayed motor neuron loss in the lumbar spinal cord, and preserved grip strength — effects comparable to riluzole, the only approved ALS drug at the time[@klivenyi1999]. Combination of creatine with minocycline provided additive neuroprotection (23% survival extension vs 12% for creatine alone)[@zhang2003].
Limited but suggestive preclinical data exist for tauopathies. In primary cortical neurons treated with okadaic acid (a tau phosphorylation inducer), creatine pretreatment (5 mM × 24h) reduced tau hyperphosphorylation at Ser396 by 40%, likely via enhanced ATP availability for protein phosphatase 2A (PP2A) function and Akt-mediated GSK-3β inhibition[@cunha2013]. These findings have not been tested in vivo in tau transgenic models, representing a significant research gap relevant to PSP and CBS.
The largest creatine trial in neurodegeneration was the NINDS Neuroprotection Exploratory Trials in PD Long-term Study 1 (NET-PD LS-1), a Phase III, randomized, double-blind, placebo-controlled futility study[@ninds2006][@writing2015]:
- Design: 1741 early PD patients (within 5 years of diagnosis, on stable dopaminergic therapy)
- Intervention: Creatine monohydrate 10 g/day vs placebo
- Duration: Minimum 5 years (median follow-up 5 years)
- Primary outcome: Modified Rankin Scale composite (clinical global outcome)
- Result: Trial stopped for futility in 2013. No difference between creatine (mean change 0.43) and placebo (0.42; p = 0.97)
- Safety: Excellent tolerability; creatine was as safe as placebo over 5 years
- Post-hoc: No benefit in any subgroup (age, disease duration, baseline severity)
The NET-PD LS-1 failure is the most definitive negative result for creatine in neurodegeneration. However, critics note that: (1) 10 g/day may exceed the capacity of the blood–brain barrier SLC6A8 transporter, with most excess creatine excreted renally; (2) the patient population may have been too advanced for neuroprotection; (3) brain creatine increases with oral supplementation are modest (5–15%) and may be insufficient to overcome the 40%+ energy deficit in PD[@dechent1999][@hass2007].
The Creatine Safety, Tolerability, and Efficacy in Huntington's Disease (CREST-E) trial was the definitive HD creatine study[@hersch2017]:
- Design: Phase III, randomized, double-blind, placebo-controlled
- Participants: 553 early HD patients
- Intervention: Creatine up to 40 g/day (titrated over 6 weeks) vs placebo
- Duration: 48 months
- Primary outcome: Total Functional Capacity (TFC) decline
- Result: Trial stopped early for futility. No difference in TFC change (creatine −1.23 vs placebo −1.42; p = 0.23)
- Safety: Weight gain and GI side effects more common in creatine group at 40 g/day, but no serious safety concerns
- Post-hoc: Trend toward benefit in patients with lower CAG repeat length (slower progressors), but not statistically significant
Three RCTs of creatine in ALS have been conducted, with uniformly negative results on primary endpoints[@groeneveld2003][@shefner2004]:
- Groeneveld et al. (2003): 175 ALS patients, creatine 10 g/day × 16 months, no benefit on survival or ALSFRS
- Shefner et al. (2004): 104 ALS patients, creatine 5 g/day × 6 months (then 10 g/day × 6 months), no benefit on MVIC strength
- Rosenfeld et al. (2008): 107 ALS patients, creatine 20 g/day × 9 months, no benefit on any endpoint
¶ Pilot Studies and Positive Signals
Despite the negative pivotal trials, several smaller studies have shown encouraging signals:
Bender et al. (2005): In 20 PD patients, creatine 20 g/day × 5 days then 5 g/day × 6 months increased brain PCr levels by 7% on MRS, improved mood (Beck Depression Inventory: −3.2 points, p = 0.02), and reduced homocysteine levels — a vascular risk factor — by 20%[@bender2006].
Forbes et al. (2004): In a crossover trial with 20 healthy elderly adults, creatine 20 g/day × 5 days then 5 g/day × 2 weeks improved working memory (random number generation task) and processing speed (Brown–Peterson task) compared to placebo[@forbes2021].
McMorris et al. (2007): In 32 older adults (age 68–85), creatine 20 g/day × 7 days improved long-term memory recall and spatial memory, with effects most pronounced in participants with lower baseline cognitive performance[@mcmorris2007].
PSP and CBS are characterized by mitochondrial dysfunction and bioenergetic failure in the basal ganglia, brainstem, and frontal cortex — regions with high metabolic demand. PET imaging with ¹⁸F-FDG demonstrates profound glucose hypometabolism in the frontal cortex and midbrain in PSP, and asymmetric frontoparietal hypometabolism in CBS[@whitwell2017]. This metabolic deficit parallels the energy failure that creatine is designed to address.
Post-mortem studies of PSP brain tissue show:
- Reduced mitochondrial Complex I activity in the substantia nigra and striatum
- Decreased total creatine (Cr + PCr) concentration in the putamen and globus pallidus
- Reduced CK activity in frontal cortex
The theoretical case for creatine in PSP/CBS rests on several convergent lines of evidence:
- Bioenergetic rescue: PSP/CBS share the mitochondrial Complex I deficit seen in PD, where creatine increases brain PCr stores by 5–15%[@dechent1999]
- Falls prevention: Creatine supplementation increases lean body mass and muscle power in elderly populations. A meta-analysis of 22 RCTs found creatine improved lower extremity strength by 5.5% in older adults[@devries2014]. For PSP patients with postural instability, this could reduce fall frequency.
- Tau phosphorylation: Creatine's enhancement of ATP availability may support PP2A activity — the primary tau dephosphorylase — and reduce GSK-3β-mediated tau hyperphosphorylation[@cunha2013]
- Frontal cognitive function: PSP is characterized by frontal-subcortical cognitive impairment. The positive cognitive effects of creatine in healthy elderly subjects (working memory, processing speed) target the same frontal circuits affected in PSP[@forbes2021][@mcmorris2007]
- Dysphagia: PSP patients develop progressive swallowing difficulty. Creatine monohydrate powder dissolves readily in warm water or can be mixed into thickened liquids. Creatine microgranule formulations offer better palatability.
- Weight: Creatine typically causes 1–2 kg weight gain from water retention. For PSP patients with progressive weight loss (common in advanced disease), this may be beneficial.
- Renal function: Monitor creatinine levels at baseline and 3 months, as creatine metabolism produces creatinine. Note that elevated serum creatinine from supplementation does not indicate renal damage — it reflects increased creatinine production, not decreased clearance[@gualano2016].
- Combination with CoQ10: Given the convergent mitochondrial targets, co-supplementation with CoQ10 (200–400 mg/day ubiquinol) is biologically rational and safe.
Based on the available evidence, the following protocol integrates creatine into comprehensive PSP/CBS management:
- Baseline assessment: Measure serum creatinine, eGFR, body weight; obtain ³¹P-MRS if available to establish baseline brain PCr/ATP ratio
- Initiation: Creatine monohydrate 5 g/day with a meal (skip loading phase to avoid GI issues in dysphagic patients)
- Monitoring: Serum creatinine at 3 months (expect 10–15% increase from supplement metabolism, not renal damage); body weight monthly
- Combination: Add CoQ10 200 mg ubiquinol for synergistic mitochondrial support; ensure adequate vitamin D for bone/muscle protection
- Adapted exercise: Combine with seated resistance training and balance exercises appropriate to disease stage
- Assessment: Re-evaluate motor function (PSP Rating Scale) and cognition (frontal assessment battery) at 6 months
- Long-term: Continue indefinitely given excellent safety profile; discontinue only if clear GI intolerance or renal function decline
| Phase |
Dose |
Duration |
Notes |
| Loading (optional) |
20 g/day in 4 divided doses |
5–7 days |
Accelerates muscle saturation; may cause GI side effects |
| Maintenance |
3–5 g/day |
Ongoing |
Single daily dose; stable brain levels achieved in 4 weeks |
| PSP/CBS recommended |
5 g/day (no loading) |
Ongoing |
Skip loading to avoid GI issues in patients with dysphagia |
| Form |
Bioavailability |
Evidence Base |
Cost |
Notes |
| Creatine monohydrate |
>90% |
Vast (>500 studies) |
Very low ($0.03/g) |
Gold standard; Creapure® brand best-characterized |
| Creatine ethyl ester |
Variable |
Limited |
Moderate |
More converts to creatinine in vivo; no advantage |
| Buffered creatine (Kre-Alkalyn) |
Similar to monohydrate |
Minimal |
High |
Marketing claims not supported by evidence |
| Creatine hydrochloride |
Similar |
Limited |
Moderate |
Better solubility but no absorption advantage |
| Creatine magnesium chelate |
Unknown |
Minimal |
High |
Insufficient evidence |
Creatine monohydrate is the only form recommended for clinical use. It is the most studied, cheapest, and has the best evidence base[@kreider2017].
A critical consideration for neurodegeneration is brain bioavailability. Creatine crosses the blood–brain barrier via the SLC6A8 creatine transporter, which has limited capacity. ³¹P-MRS studies show that oral creatine supplementation (20 g/day × 4 weeks) increases brain total creatine by only 5–15%, with higher increases in vegetarians (who have lower baseline brain creatine)[@dechent1999][@brosnan2016]. This modest brain uptake contrasts with the 20–40% increase in muscle PCr, suggesting that the BBB is rate-limiting. Strategies to enhance brain creatine delivery — including cyclocreatine (a CK substrate analog with better BBB penetrance) and intranasal delivery — are under investigation[@lunardi2006].
¶ Drug Interactions and Safety
The NET-PD LS-1 trial provided the most comprehensive safety data: 10 g/day creatine for a median of 5 years in 1741 PD patients showed no increase in adverse events versus placebo, including renal function, liver enzymes, and cardiovascular events[@writing2015]. This represents the gold standard safety dataset for any dietary supplement in neurodegeneration.
| Drug |
Interaction |
Management |
| NSAIDs (ibuprofen, naproxen) |
Theoretical reduction in creatine uptake |
Separate dosing by 2+ hours |
| Nephrotoxic drugs (aminoglycosides, cyclosporine) |
Additive renal stress |
Monitor creatinine; reduce creatine dose or discontinue |
| Caffeine |
May reduce creatine's ergogenic effects on muscle (no evidence for CNS interaction) |
No action needed for neuroprotection indication |
| Metformin |
Both affect AMPK signaling; possible synergy |
No dose adjustment |
| Levodopa |
No known interaction |
Safe to combine |
- Pre-existing severe renal impairment (eGFR < 30 mL/min)
- Active nephrolithiasis (kidney stones)
- Known hypersensitivity to creatine
The consistent failure of creatine in pivotal NDD trials despite strong preclinical data offers important lessons:
- Insufficient brain uptake: The 5–15% increase in brain creatine may be below the therapeutic threshold. The energy deficit in PD is estimated at 30–40%, suggesting that creatine alone cannot fully compensate[@hass2007].
- Too-late intervention: NET-PD LS-1 enrolled patients within 5 years of PD diagnosis, but neurodegeneration begins years before clinical onset. A prevention or prodromal trial might show different results.
- Wrong endpoint: Clinical scales (UPDRS, TFC) may be insensitive to creatine's neuroprotective effects. Biomarker-driven endpoints (MRS PCr/ATP, NfL) could detect subtle benefits.
- Monotherapy limitation: Energy failure is one of many interacting pathological mechanisms. Creatine may need to be combined with agents addressing inflammation (curcumin), oxidative stress (NAD+ precursors), or tau aggregation to achieve clinically meaningful effects.
- Individual variation: SLC6A8 transporter polymorphisms and dietary creatine intake (vegetarians vs omnivores) create substantial inter-individual variation in brain creatine response[@brosnan2016].
- CoQ10: Creatine (CK shuttle) + CoQ10 (electron transport chain Complex I/III) provides complementary mitochondrial support. Combination trials are ongoing[@li2015].
- Alpha-lipoic acid: Mitochondrial cofactor + antioxidant; may enhance creatine's anti-oxidant effects.
- Exercise: Physical activity increases creatine utilization and independently improves mitochondrial function. The combination is especially important for PSP patients (adapted exercise + falls prevention).
- Mediterranean/MIND diet: Dietary patterns supporting mitochondrial health complement creatine supplementation.
- Vitamin D: Addresses the muscle weakness and falls risk that creatine also targets; combination may be synergistic for PSP.
¶ Research Gaps and Future Directions
- PSP/CBS trial: No clinical trial has tested creatine in PSP or CBS. A pilot study with MRS PCr/ATP as primary endpoint could be completed in 20–30 patients.
- Cyclocreatine and prodrugs: Creatine analogs with better BBB penetrance could overcome the brain uptake limitation[@lunardi2006].
- Intranasal delivery: Bypassing the BBB via olfactory/trigeminal routes could dramatically increase brain creatine concentrations.
- Prevention trials: Testing creatine in prodromal PD (REM sleep behavior disorder cohorts) or presymptomatic HD (gene-positive, pre-manifest) would address the timing concern.
- Combination trials: Creatine + CoQ10 + exercise as a multimodal bioenergetic intervention deserves systematic evaluation.
- Vegetarian subgroup: Given that vegetarians have lower baseline brain creatine and show greater supplementation response, this population may represent an enriched responder group[@brosnan2016].
- Creatine + resistance exercise in PSP: A feasibility study combining creatine 5 g/day with adapted seated resistance training in PSP patients could assess effects on falls frequency, muscle strength, and frontal cognitive function using the PSP Rating Scale and Frontal Assessment Battery as co-primary outcomes.
- Wallimann T, Tokarska-Schlattner M, Schlattner U, The creatine kinase system and pleiotropic effects of creatine (2011)
- Wyss M, Kaddurah-Daouk R, Creatine and creatinine metabolism (2000)
- Beal MF, Energetics in the pathogenesis of neurodegenerative diseases (2000)
- Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J, Increase of total creatine in human brain after oral supplementation of creatine-monohydrate (1999)
- Aksenov M, Aksenova M, Butterfield DA, Markesbery WR, Oxidative modification of creatine kinase BB in Alzheimer's disease brain (2000)
- Kim J, Moody JP, Edgerly CK, et al, Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease (2010)
- Balestrino M, Rebaudo R, Bhatt S, Delay of anoxic depolarization by creatine in hippocampal slices (1999)
- O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T, The role of creatine kinase in inhibition of mitochondrial permeability transition (1997)
- Dolder M, Walzel B, Speer O, Schlattner U, Wallimann T, Inhibition of the mitochondrial permeability transition by creatine kinase substrates (2003)
- Brewer GJ, Wallimann TW, Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons (2000)
- Lawler JM, Barnes WS, Wu G, Song W, Demaree S, Direct antioxidant properties of creatine (2002)
- Andreassen OA, Dedeoglu A, Ferrante RJ, et al, Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease (2001)
- Cunha MP, Martín-de-Saavedra MD, Romero A, et al, Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: involvement of intracellular signaling pathways (2013)
- Lenz H, Schmidt M, Welge V, et al, Inhibition of cytosolic and mitochondrial creatine kinase by siRNA in HaCaT- and HeLaS3-cells affects cell viability and mitochondrial morphology (2007)
- Matthews RT, Ferrante RJ, Klivenyi P, et al, Creatine and cyclocreatine attenuate MPTP neurotoxicity (1999)
- Andres RH, Ducray AD, Perez-Bouza A, et al, Creatine supplementation improves dopaminergic cell survival and protects against MPP+ induced neurotoxicity in a Parkinson's disease model (2005)
- Matthews RT, Yang L, Jenkins BG, et al, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease (1998)
- Klivenyi P, Ferrante RJ, Matthews RT, et al, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis (1999)
- Zhang W, Narayanan M, Bhatt S, Neuroprotective effects of combination of creatine and minocycline in ALS model (2003)
- NINDS NET-PD Investigators, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2006)
- Writing Group for the NINDS Exploratory Trials in Parkinson Disease Investigators, Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial (2015)
- Hass CJ, Collins MA, Juncos JL, Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial (2007)
- Hersch SM, Schifitto G, Oakes D, et al, The CREST-E study of creatine for Huntington disease: a randomized controlled trial (2017)
- Groeneveld GJ, Veldink JH, van der Tweel I, et al, A randomized sequential trial of creatine in amyotrophic lateral sclerosis (2003)
- Shefner JM, Cudkowicz ME, Schoenfeld D, et al, A clinical trial of creatine in ALS (2004)
- Bender A, Koch W, Elstner M, et al, Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial (2006)
- Forbes SC, Candow DG, Ostojic SM, Roberts MD, Chilibeck PD, Meta-analysis examining the importance of creatine ingestion strategies on lean tissue mass and strength in older adults (2021)
- McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A, Creatine supplementation and cognitive performance in elderly individuals (2007)
- Whitwell JL, Höglinger GU, Antonini A, et al, Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? (2017)
- Devries MC, Phillips SM, Creatine supplementation during resistance training in older adults—a meta-analysis (2014)
- Gualano B, Rawson ES, Candow DG, Chilibeck PD, Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain (2016)
- Kreider RB, Kalman DS, Antonio J, et al, International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017)
- Brosnan ME, Brosnan JT, The role of dietary creatine (2016)
- Lunardi G, Parodi A, Perasso L, et al, The creatine transporter mediates the uptake of creatine by brain tissue, but not the analog cyclocreatine (2006)
- Li Z, Wang P, Yu Z, et al, The effect of creatine and coenzyme Q10 combination therapy on mild cognitive impairment in Parkinson's disease (2015)